Shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) traded up 5.7% on Monday . The stock traded as high as $4.01 and last traded at $3.87. 2,159,066 shares changed hands during trading, a decline of 93% from the average session volume of 32,192,027 shares. The stock had previously closed at $3.66.
Wall Street Analyst Weigh In
A number of analysts have weighed in on SANA shares. JMP Securities cut shares of Sana Biotechnology from an "outperform" rating to a "market perform" rating in a report on Tuesday, November 5th. HC Wainwright increased their price objective on shares of Sana Biotechnology from $8.00 to $11.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Finally, TD Cowen upgraded Sana Biotechnology from a "hold" rating to a "buy" rating in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $14.25.
Check Out Our Latest Stock Report on SANA
Sana Biotechnology Stock Up 6.3 %
The firm's 50-day moving average price is $2.40 and its 200 day moving average price is $4.02. The firm has a market cap of $861.82 million, a P/E ratio of -2.76 and a beta of 1.45.
Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its earnings results on Friday, November 8th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. On average, equities analysts predict that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.
Insiders Place Their Bets
In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of the business's stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the sale, the insider now directly owns 4,541,511 shares in the company, valued at approximately $29,474,406.39. The trade was a 6.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 31.10% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. FMR LLC increased its position in shares of Sana Biotechnology by 16.3% during the 3rd quarter. FMR LLC now owns 31,609,175 shares of the company's stock valued at $131,494,000 after purchasing an additional 4,438,949 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Sana Biotechnology by 9.6% in the third quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company's stock valued at $13,175,000 after buying an additional 276,055 shares during the period. State Street Corp boosted its stake in Sana Biotechnology by 4.2% during the third quarter. State Street Corp now owns 6,627,320 shares of the company's stock valued at $27,570,000 after buying an additional 269,274 shares in the last quarter. Integral Health Asset Management LLC grew its holdings in Sana Biotechnology by 22.4% during the second quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company's stock worth $6,552,000 after acquiring an additional 220,000 shares during the period. Finally, Barclays PLC raised its position in Sana Biotechnology by 126.6% in the third quarter. Barclays PLC now owns 318,910 shares of the company's stock worth $1,325,000 after acquiring an additional 178,179 shares in the last quarter. Institutional investors and hedge funds own 88.23% of the company's stock.
About Sana Biotechnology
(
Get Free Report)
Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.
Featured Stories
Before you consider Sana Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sana Biotechnology wasn't on the list.
While Sana Biotechnology currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
